ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy productsThere is considerable interest in the next generation of personalized medicine, especially cell and gene therapy products such as chimeric antigen receptor T cells (CAR-Ts). Unlike other small molecules or pharmacologic drugs, most existing cell or cell-based gene therapy products (CGTs) require apheresis collection of the patient or donor, subsequent manufacture of the product, and final shipment of the product to the clinical site for infusion. Whereas traditional pharmaceutical drugs have involved the drug sponsor and the clinical site and clinical pharmacy, this new manufacturing paradigm has evolved, in many cases, to include an apheresis center, a cell processing lab, the sponsor's manufacturing facility, and a clinical site with or without a pharmacy.
Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experienceCellular immunotherapy is the application of immune cells that are collected, and often modified ex vivo, to improve immune responses for a patient's treatment. The Foundation for the Accreditation of Cellular Therapy (FACT) defines immune effector cells (IECs) as cells designed to modulate immune responses for therapeutic purposes and includes cells such as T cells, B cells, natural killer (NK) cells and dendritic cells . Many of these types of cells may be genetically modified to further enhance their cellular function.